- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03038009
Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft (DACAB-GI-2)
Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Endoscopic evaluation of gastroduodenal mucosal injury:
Based on the modified Lanza score, the new endoscopic evaluation system established in the DACAB-GI-1 study includes 6 grades of mucosal injuries. Grade 0: normal mucosa; Grade 1: erythema or petechiae only; Grade 2: 1 to 2 erosive lesions; Grade 3: 3 to 10 erosive lesions; Grade 4: more than 10 erosive lesions or small ulcers (diameter: 3-5mm); Grade 5: an ulcer is greater than 5 mm in diameter. Comprehensive results of gastroduodenal mucosal injury will be marked as G0-5 (G: gastro) and D0-5 (D: duodeno) together. Mild injury was defined as level II or less. Severe injury was defined from level III to V, which should be treated with proton pump inhibitor (PPI) to decrease the risk of upper GI bleeding. The new level system is as following: Level 0: G0D0; Level I: G1D0-1/G0D1; Level II: G2D0-2/G0-1D2; Level III: G3D0-3/G0-2D3; Level IV: G4D0-4/G0-3D4; Level V: G5D0-5/G0-4D5.
Sample size justification:
Until now, no published data or reference is available for the efficacy of pantoprazole when concomitant use with DAPT. The results from the preliminary study (DACAB-GI-1) showed that the percentage of serious gastroduodenal mucosal lesions (Level III-V) in patients treated with PPIs for 1, 3 and more than 6 months were 36.76%, 28.45% and 17.65%, respectively. Therefore, the efficacy difference of pantoprazole is estimated to be 18% between 2 groups. The average incidence of gastroduodenal mucosal injury is estimated to be 36% in the control group (1-month therapy of pantoprazole), and the corresponding incidence in the experimental group (12-month therapy of pantoprazole) is estimated to be 18%.
The determination of minimal sample size is as following: Group sample sizes of 93 in the experimental group and 93 in the control group achieve 80% power to detect a difference between the group proportions of -18%. The proportion in the experimental group is assumed to be 36% under the null hypothesis and 18% under the alternative hypothesis. The proportion in the control group is 36%. The test statistic used is Pearson Chi-Squared test. The significance level of the test was targeted at 0.05. The significance level actually achieved by this design is 0.0522. Considering 10% of the lost and/or drop-out rate, the final sample size estimated will be 104 in the experimental group and control group, respectively. The total sample size is no less than 208.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200025
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Each patient should meet all of the inclusion criteria and none of the exclusion criteria for this study:
- Provision of informed consent prior to any study specific procedures.
- CABG surgery is performed for the first time.
- Need 12-month DAPT (aspirin 100mg qd plus clopidogrel 75mg qd or aspirin 100mg qd plus ticagrelor 90mg bid depending on randomisation) immediately following CABG surgery according to the guideline.
- Concomitant use of pantoprazole (40mg qd) for at least 1 moth following CABG surgery.
- Willing to undergo EGD twice a year (at 6th and 12th month following CABG surgery, respectively).
- Willing to undergo 13C-UBT prior to CABG surgery.
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled.
- History of previous active peptic ulcer within 3 months prior to enrollment.
- Planned use of PPI to treat gastric-acid associated diseases (e.g. gastroesophageal reflux disease, GERD)
- Contraindications for aspirin, clopidogrel, ticagrelor and pantoprazole use (e.g. known allergy)
Anticipated concomitant oral or intravenous therapy with strong cytochrome P450 3A4 (CYP3A4) inhibitors or CYP3A4 substrates with narrow therapeutic indices, that cannot be stopped for the course of the study.
- Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir
- CYP3A4 substrates with narrow therapeutic index: quinidine, simvastatin at doses > 40mg daily or lovastatin at doses > 40mg daily.
- Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin.
- History of previous intracerebral bleeding at any time, GI bleeding within the past 3 months prior to enrollment, or major surgery within 30 days prior to enrollment.
- Known moderate to severe liver disease (e.g. gastroesophageal varices, ascites and/ or clinical signs of coagulopathy)
- Renal failure requiring dialysis.
- Women of child-bearing potential who are not willing to use a medically accepted method of contraception that is considered reliable in the judgement of investigator OR women who have a positive pregnancy test at enrolment or randomisation OR women who are breasting-feeding.
- Inability of patient to understand and/or comply with study procedures and/or follow up, in the opinion of the investigator, OR any conditions that, in the opinion of the investigator, many render the patient unable to complete the study.
- Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, long-term concomitant treatment with non-steroidal anti-inflammatory drugs [NSAIDs]), or any condition outside the atherothrombotic study area with a life expectancy of less than 2 years based on investigator's judgement.
- Paticipation in another clinical study with an investigational product within 28 days prior to enrolment or previous randomization to an investigational product in another ongoing clinical study. Participation in any previous study with clopidogrel or tigagrelor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: One-month therapy
Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
|
Pantoprazole (40mg qd) will be concomitant used with DAPT
Other Names:
|
Experimental: Twelve-month therapy
Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
|
Pantoprazole (40mg qd) will be concomitant used with DAPT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative incidence of gastroduodenal erosions and ulcers.
Time Frame: up to 12 months
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of gastroduodenal erosions and ulcers.
Time Frame: up to 6 months
|
up to 6 months
|
|
Incidence of upper GI major bleeding according to TIMI criteria.
Time Frame: up to 12 months
|
up to 12 months
|
|
Incidence of upper GI minor bleeding according to TIMI criteria
Time Frame: up to 12 months
|
up to 12 months
|
|
Incidence of major cardiovascular events (MACE, composite of cardiovascular death, myocardial infarctions, or stroke).
Time Frame: up to 12 months
|
Safety Issue: Yes
|
up to 12 months
|
Incidence of grafts failure.
Time Frame: up to 12 months
|
Safety Issue: Yes
|
up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lifen Yu, MD, Ph.D, Ruijin Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Duodenal Diseases
- Ulcer
- Stomach Ulcer
- Peptic Ulcer
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Pantoprazole
Other Study ID Numbers
- IISR-2016-101603
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Ulcer Induced by Antiplatelet Agent
-
King Chulalongkorn Memorial HospitalCompletedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet AgentThailand
-
The University of Hong KongTerminatedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet Agent | OGDChina, Hong Kong
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol Specific | Drug/Agent Toxicity by Tissue/OrganUnited States
-
Rush North Shore Medical CenterCompletedUnspecified Adult Solid Tumor, Protocol Specific | Drug/Agent Toxicity by Tissue/OrganUnited States
-
Eisai Co., Ltd.CompletedGastric Ulcers Duodenal Ulcers Caused by Low-dose AspirinJapan
-
NYU Langone HealthNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Drug/Agent Toxicity by Tissue/OrganUnited States
-
Hamamatsu UniversityYokoyama Foundation for Clinical PharmacologyUnknownGastric Cancer | Gastric Ulcer | Duodenal UlcerJapan
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedLeukemia | Drug/Agent Toxicity by Tissue/OrganUnited States
-
University of ArizonaCompletedBreast Cancer | Drug/Agent Toxicity by Tissue/OrganUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedBreast Cancer | Drug/Agent Toxicity by Tissue/OrganUnited States
Clinical Trials on Pantoprazole
-
AbbottCompleted
-
Kwong Wah HospitalCompleted
-
Alexandria UniversityCompletedPortal Hypertension | Variceal Hemorrhage | Ulcer HemorrhageEgypt
-
PfizerRecruitingEsophagitisBelgium, United States, United Kingdom, Serbia, Georgia, Hungary, Bosnia and Herzegovina, Puerto Rico, Turkey, Slovakia, India
-
National Taiwan University HospitalUnknownBleeding | Peptic Ulcer | Endoscopy | Proton Pump InhibitorsTaiwan
-
TakedaWithdrawnGastric pH ControlMexico
-
University of Auckland, New ZealandCompletedBreast Cancer | Chemotherapy-induced Nausea and Vomiting | OncologyNew Zealand
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedGastroesophageal Reflux
-
PfizerTerminatedGastroesophageal Reflux DiseaseUnited States, Bosnia and Herzegovina, Slovakia, Italy, Germany, Argentina, Georgia, Serbia, Ukraine
-
Emory UniversityWyeth is now a wholly owned subsidiary of PfizerCompleted